文献速递心力衰竭与心肌病心律失常

扩张型心肌病高危心律失常基因型与晚期心衰风险

Arrhythmic genotypes in dilated cardiomyopathy and risk of advanced heart failure.
PubMed 文献 · Eur Heart J · 2025-01-01

本研究基于西班牙19个中心1203例基因分型扩张型心肌病患者,按基因型分为高危心律失常基因组、TTN组、其他基因组和基因阴性组,中位随访5.7年。结果显示高危心律失常基因型患者晚期心衰事件发生率更高(24.3% vs 其他组),且为晚期心衰的独立预测因素,提示该组患者除预防猝死外需差异化治疗。

要点

  • 高危心律失常基因型(LMNA、FLNC、桥粒基因等)与晚期心衰事件风险增加独立相关。
  • 高危基因型患者晚期心衰事件发生率24.3%,高于其他基因组18.7%、TTN组13.0%和基因阴性组10.1%。
  • 高危基因型与晚期钆增强均为恶性室性心律失常的独立预测因素。

核心结论

  • 高危心律失常基因型扩张型心肌病患者晚期心衰事件风险显著增加,支持对该组患者采取超越猝死预防的差异化治疗策略。

研究设计与样本

  • 多中心回顾性队列研究,纳入西班牙19个中心1203例已基因分型的扩张型心肌病患者。
  • 按基因型分为高危心律失常基因组(LMNA、FLNC、桥粒基因、PLN、TMEM43、RBM20)、TTN组、其他基因组和基因阴性组。
  • 主要终点为晚期心衰事件复合终点(心室辅助装置植入、心脏移植、心衰相关死亡),次要终点为恶性室性心律失常复合终点。

主要发现

  • 高危心律失常基因变异见于185例(15.4%),TTN变异193例(16.0%),其他基因变异134例(11.1%),基因阴性691例(57.4%)。
  • 中位随访5.7年(四分位距2.9-9.1年),高危心律失常组晚期心衰事件45例(24.3%),其他基因组25例(18.7%),TTN组25例(13.0%),基因阴性组70例(10.1%)。
  • 高危心律失常基因与其他组相比,晚期心衰事件风险比1.85(95%CI 1.31-2.61)。
  • 恶性室性心律失常发生于55例(29.7%),高危基因型与其他组相比风险比2.52(95%CI 1.81-3.51)。
  • 多变量分析显示高危心律失常基因型是晚期心衰的主要独立预测因素;高危基因型和晚期钆增强是恶性室性心律失常的独立预测因素。

临床怎么用

  • 对扩张型心肌病患者进行基因分型,识别高危心律失常基因型(如LMNA、FLNC、桥粒基因等)。
  • 对高危基因型患者除评估猝死风险外,应加强心衰进展监测和晚期心衰管理。
  • 高危基因型合并晚期钆增强者恶性室性心律失常风险更高,需强化心律失常监测。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND AIMS: Certain genetic forms of dilated cardiomyopathy (DCM) entail a higher arrhythmic risk. It is unknown whether DCM patients with high-risk arrhythmic genotypes also develop more advanced heart failure (AHF) complications. AHF events were studied according to DCM genotype. METHODS: Clinical data from 1203 genotyped DCM patients were collected from 19 Spanish centres. Patients were classified into high-risk arrhythmic genotypes (LMNA, FLNC, desmosomal genes, PLN, TMEM43, RBM20), TTN, other genes, and genotype negative (Gen-). The primary endpoint was a composite of AHF events (ventricular assist device implantation, heart transplant, and AHF-related mortality). The secondary endpoint was a combination of malignant ventricular arrhythmias (MVA). RESULTS: A DCM-causing variant was identified in a high-risk arrhythmic gene in 185 patients (15.4%), 193 (16.0%) had variants in TTN, 134 (11.1%) in other genes, and 691 (57.4%) were Gen-. After a median follow-up of 5.7 years (interquartile range 2.9-9.1 years), AHF events occurred in 45 (24.3%) patients in the high-risk arrhythmic group, while in 25 (18.7%), 25 (13.0%), and 70 (10.1%) patients with other genotypes, TTN, and Gen-, respectively (hazard ratio 1.85, 95% confidence interval 1.31-2.61 for high-risk arrhythmic genes compared with other groups). MVA occurred in 55 patients (29.7%) (hazard ratio 2.52, 95% confidence interval 1.81-3.51 for high-risk genotypes vs other groups). High-risk arrhythmic genotype was the main independent predictor of AHF in multivariate analysis. High-risk arrhythmic genotype and late gadolinium enhancement were independent predictors of MVA. CONCLUSIONS: Patients with high-risk arrhythmic genotypes also experience more AHF events, supporting a differential therapeutic approach in this group of patients beyond sudden death prevention.

来源:Eur Heart J,查看原文。版权归原作者所有。

引用

  1. Mora-Ayestarán, Ochoa, Gómez-González, et al. Arrhythmic genotypes in dilated cardiomyopathy and risk of advanced heart failure. Eur Heart J. 2025. PMID: 40878535. doi:10.1093/eurheartj/ehaf605

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。